Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug
1. TELO shares surged by 20.3% on significant trading volume. 2. Telomir-1 shows promise in reducing TNBC cell viability in lab studies. 3. Telomir plans further studies on additional cancer types for drug development. 4. Stock price is approaching its 52-week low of $1.12.